How to administer

This website is intended for healthcare professionals outside of the US and UK

ELAPRASE dosing is based on the weight of the patient. ELAPRASE is administered at a dose of 0.5 mg/kg body weight every week by intravenous infusion over a 3 hour period, which may be gradually reduced to 1 hour if no infusion-associated reactions are observed.1

Several resources are available to provide information about how to administer ELAPRASE:

Animated video of how to dose and administer ELAPRASE

The following animated video explains how to calculate the correct dose of ELAPRASE for a Hunter syndrome patient and how to administer the treatment.

Online dose calculator for ELAPRASE

The online dose calculator requires you to enter the patient weight (in kilograms), and then uses the recommended dose of ELAPRASE (0.5 mg/kg) and the supplied concentration of ELAPRASE solution (2 mg/ml) to calculate the volume of ELAPRASE required for dilution and infusion.

*Required fields


Please enter the patient weight in kilograms (kg)

Calculate Restart

A dosing reference wheel for ELAPRASE

A dosing reference wheel displaying example dose calculations may be available in your country; contact a local Takeda representative to find out more.


A dosing infographic for ELAPRASE

The following infographic explains how to calculate the correct dose of ELAPRASE for a Hunter syndrome patient and the ELAPRASE dosing regimen.


All information in this infographic has been taken from the ELAPRASE summary of product characteristics. Treatment decisions should be based on the judgement of each individual patient by their physician.

Download now

Frequently asked questions about ELAPRASE

What is the dosing schedule for ELAPRASE?

Why is the ELAPRASE dose weight-based?

Can you round the dose of ELAPRASE to the nearest whole vial?

How does ELAPRASE work?

Can ELAPRASE infusions take place at home?

When is it best to start treatment with ELAPRASE?

How should I store ELAPRASE?

How should I dispose of any unused ELAPRASE?

Is a dose adjustment required in patients with hepatic or renal insufficiency?

What were the common adverse events associated with ELAPRASE?


  1. Elaprase Summary of Product Characteristics. 2020

  2. Whiteman DAH and Kimura A. Drug Design, Development and Therapy. 2017;11:2467-2480.

  3. Muenzer J, Beck M, Giugliani R et al. Genet Med. 2011;13(2):102-109.